Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Dec 24, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
December 2015 PDF



 

Multiple Myeloma

Head-to-Head Phase III Study Demonstrates Kyprolis Nearly Doubles PFS over Velcade

Results from the phase III head-to-head ENDEAVOR study comparing Kyprolis to Velcade in patients with relapsed multiple myeloma showed that patients treated with Kyprolis achieved progression-free survival of 18.7 months compared to 9.4 months (HR=0.53; 95% CI: 0.44, 0.65; p<0.0001).

The findings demonstrated that patients treated with Kyprolis (carfilzomib) plus dexamethasone lived twice as long without disease worsening as those treated with Velcade (bortezomib) plus dexamethasone.

Also:

 

Leukemia

AML Patients Receiving PKC412 Midostaurin Show 23% OS Improvement in Phase III Trial

Adult patients under 60 years of age with newly-diagnosed FLT3-mutated acute myeloid leukemia who received the investigational compound PKC412 (midostaurin), plus standard induction and consolidation chemotherapy, experienced a 23 percent improvement in overall survival (HR=0.77, p=0.0074), compared to those treated with standard induction and consolidation chemotherapy alone.

In the phase III RATIFY clinical trial, the median OS for patients in the PKC412 treatment group was 74.7 months (95% CI: 31.7, not attained), versus 25.6 months (95% CI: 18.6, 42.9) for patients in the placebo group.

The trial evaluated the addition of either PKC412 or placebo to daunorubicin/cytarabine in the induction phase, followed by high-dose cytarabine in the consolidation phase; patients who achieved complete remission after consolidation chemotherapy continued treatment with PKC412 or placebo as a single agent for up to one year.

     

    Drugs and Targets

    FDA Approves Opdivo Injection for Renal Cell Carcinoma Patients

    FDA approved Opdivo (nivolumab) injection for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

    In the CheckMate-025 trial, patients treated with Opdivo achieved a median OS of 25 months (95% CI: 21.7-not estimable) versus 19.6 months (95% CI: 17.6-23.1) for everolimus, a current standard of care (HR: 0.73; [95% CI: 0.60-0.89; p=0.0018]), based on a prespecified interim analysis. In the study, the safety profile was consistent with prior Opdivo studies.

    Also:

     

    Pancreatic Cancer

     

    Liver Metastases

    Phase III Melphalan Trial Shows Improvement in Hepatic-PFS in Melanoma Patients



    To access this members-only content, please log in.

    If you're not a subscriber why not join today?

    If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


    To gain access to the members only content click here to subscribe.

    You will be given immediate access to premium content on the site.

    Letter